ACN — Accenture plc

Sentiment flipped hard positive on the Oct 1, 2026 print: Q4 revenue of $18.7B beat the high end of guidance, GAAP EPS of $3.29 topped the $3.18 consensus, Q4 bookings were $22.2B (+5% local currency), and management added 400+ AI clients in FY26. The stock jumped roughly 15-20% and is up 44.81% over three months (per the 2026-10-04 technical feed), with sell-side targets chased higher - Goldman Sachs $230 to $260, Argus to $260, UBS reiterating $275, Jefferies $190 to $220. The rally is explicitly a refutation of the 'GenAI eats billable hours' bear case, not just an earnings beat.

Stable mid-single-digit grower with real margin expansion, not an accelerating story. Revenue YoY: Q1 FY26 +5.9%, Q2 FY26 +8.3%, Q3 FY26 +5.6%, Q4 FY26 +6.2% - FY26 totaled $74.18B, +6.5% reported / +5% local currency, versus FY25's +7.4%. Sequential Q4 revenue was essentially flat (-0.2% vs Q3's $18.72B). The profit line is the better story: FY26 operating margin was 15.8% (OI $11.71B) versus 14.7% in FY25, roughly +110bp, and Q4 FY26 operating margin of 15.5% compares to a distorted 11.6% in Q4 FY25 (that quarter carried an $817M 'R&D expense' line that appears nowhere else in the 12-quarter set). FY26 diluted EPS of $13.56 (+11.6%) accelerated over FY25's $12.15 (+6.3%). Cash flow: FY26 FCF $11.62B vs $10.87B (+6.9%) and FY26 OCF $12.36B (+7.7%) - but Q4 FY26 OCF fell 20.9% YoY ($3.095B vs $3.914B) against an unusually strong prior-year quarter. Verdict: durable, modest growth plus margin/cash discipline; the Q4 OCF dip is a comparison blip, not a deterioration, but nothing here says reacceleration either.

Cheap versus its own history, and cheap versus its quality metrics. As of 2026-10-04, at $198.90: TTM P/E 14.56 against a 5-year average of 24.17; P/S 1.64 against a 5-year average of 2.67; forward P/E of ~13.5x on next-FY consensus EPS of $14.692; PEG 1.31; EV/EBITDA 8.60; P/B 3.79 with ROE of 26.5% and ROIC of 16.8%. FY26 FCF of $11.62B on a ~$121.7B market cap is a ~9.5% free-cash-flow yield - unusually high for a net-cash, 16%-ROIC services franchise. The data feed reports a 4.69% dividend yield, but the announced $1.71/quarter dividend ($6.84 annualized, a 5% raise, ~50% of FY26 GAAP EPS) implies ~3.4% at $198.90; I'd treat the 4.69% figure as stale/price-mismatched. Even at 3.4%, this is a low-teens-earnings-multiple, high-cash-return setup - the discount is the market's price for unresolved AI-disruption risk, not a data error.

The 44.81% three-month gain was mostly multiple, not earnings. Three months ago the implied price was ~$137 (198.90 / 1.4481) on FY25 EPS of $12.15 - roughly 11x. Today it is 14.56x TTM and 13.5x forward on EPS of $14.692. So the market moved from pricing terminal AI-driven decline to pricing a normal low-teens grower, without any change in the FY27 revenue guide, which is 3-6% local currency (midpoint 4.5%, i.e. a slight deceleration from FY26's +5% local currency). Read it this way: earnings are being delivered (EPS +11.6% in FY26, dividends +5%, $11.5B returned to shareholders), but the stock now needs bookings and AI revenue to keep validating the re-rating. If FY27 bookings fail to accelerate past +5% local currency, the multiple has no further room; if AI programs convert as management claims, 13.5x forward is the mispricing.

As of 2026-10-04, RSI(14) stood at 59.07 - firm but not overbought. Price was +7.34% above its 20-day SMA (~$185), +10.44% above its 50-day (~$180), and +1.52% above its 200-day (~$196), i.e. a fresh bullish MA stack after a long downtrend, with the 200-day just reclaimed. Returns: +12.94% one week, +5.98% one month, +44.81% three months, -1.21% six months, inside a 52-week range of $118.15-$291.09. The stock fell roughly 60% from its 52-week high before this rally, so the current level is a recovery, not a breakout to new highs. Entry implication: level matters a lot - buying mid-rally after a 45% three-month move is chasing; the higher-probability add zones are a retest of the 200-day (~$196) or the $175-180 area, and the 52-week high at $291 is the obvious overhead reference. Also be aware the feed's own price ($198.90) versus prior close ($212.30) shows a -6.3% day that contradicts the +12.94% week, so don't over-trust any single print.

• Enterprise IT budget mix is rotating from traditional consulting/run-rate work into GenAI programs - Accenture is capturing share of that shift (400+ AI clients added in FY26, emerging alliances with Nvidia, OpenAI, Palantir, Anthropic) rather than losing it, but the mix shift pressures legacy billable-hour pricing.
• The GenAI disintermediation thesis (AI automating the labor Accenture sells) is the single biggest driver of the stock's multiple - it took the shares from $291 to $118 before FY26 results partially refuted it; it is not resolved, only deferred.
• Government and public-sector demand was a notable FY26 tailwind but is politically volatile - US federal cost-cutting initiatives and shifting fiscal/regulatory backdrops make those contracts lumpy, and some analysts explicitly warn certain government tailwinds may not repeat in FY27.
• Rate and duration sensitivity: with a ~9.5% FCF yield and a 3.4% dividend yield on 50%-of-EPS payout plus heavy buybacks, ACN trades partly as a cash-return/duration asset - moves in the discount rate and equity risk premium re-rate this stock as much as earnings do.
• Currency: roughly half of revenue is non-USD, and FY26 local-currency growth of +5% came in below the +6.5% reported figure, so FX was a reported-revenue tailwind; a reversal in the dollar, plus Indian delivery-cost wage inflation, would hit reported growth and margin simultaneously.

• Investor & Analyst Day on 2026-10-14 - management's platform for multi-year growth targets, margin-expansion path, and the new Accenture Construct (capital projects) unit; a soft multi-year framework would undercut the re-rating.
• Q1 FY27 earnings on 2026-12-17 (estimated) - the first hard test of the 3-6% local-currency FY27 guide and, more importantly, whether the $22.2B Q4 bookings pace and AI revenue disclosures keep compounding.
• AI alliance monetization at scale - Nvidia, OpenAI, Palantir, the Anthropic safety partnership, and the AWS Marketplace mid-market cloud/AI rollout are the forward indicators of whether AI pilots convert into the large transformation contracts management claims.
• Continued capital return - the 5% dividend raise to $1.71/quarter (payable 2026-11-13) and a record $11.5B returned in FY26; further buyback acceleration at a 13.5x forward multiple would be highly accretive.
• Multiple re-rating optionality - at 13.5x forward versus a 24.17x 5-year average, even a partial normalization toward a 16-18x forward multiple is worth 15-30% without any earnings upgrade.

• AI cannibalization of traditional consulting and managed-services revenue remains the core unresolved bear case - FY26 pushed it back but did not kill it, and any quarter showing decelerating bookings or AI-driven pricing deflation would hit the multiple hard.
• Growth is decelerating at the margin: FY27 guidance of 3-6% local currency (midpoint 4.5%) is below FY26's +5% local currency achievement, and Q4 bookings growth of +5% local currency is not the acceleration a 14x+ multiple now requires.
• Government contract lumpiness - FY26 public-sector strength that analysts flag as possibly non-repeating, plus ongoing US federal cost-cutting pressure, could leave a hole in FY27 bookings.
• Unexplained balance-sheet shift: long-term debt nearly doubled to $9.999B in Q4 FY26 from $5.029B in Q3 FY26, while the net-cash cushion narrowed to ~$2.8B from ~$6.4B a year earlier - the research brief does not explain it, and if it funds a large acquisition, integration and dilution risk follow.
• Cash-conversion wobble - Q4 FY26 operating cash flow fell 20.9% YoY to $3.095B; one quarter is noise against a strong comparable, but two in a row would undermine the cash-return story that supports the valuation.
• The recent 44.81% three-month move was multiple-driven - if AI spending conversion stalls, there is little earnings cushion underneath, and the 52-week low of $118.15 is a live reference point.

This is a fair-quality business at a genuinely discounted price, and the honest read is that it is a reasonable risk/reward rather than a screaming buy after a 45% three-month run. The numbers are solid, not spectacular: FY26 revenue +6.5% reported / +5% local currency, operating margin up ~110bp to 15.8%, EPS +11.6% to $13.56, FCF of $11.62B (a ~9.5% yield), ROIC of 16.8%, net cash, and $11.5B returned to shareholders against a 13.5x forward multiple and a 24.17x 5-year average. What is unresolved - and what the price ultimately hinges on - is whether GenAI makes Accenture's billable hours redundant or makes it the integrator that monetizes them; FY26 bookings and 400+ new AI clients argue for the latter, but FY27 guidance of 3-6% is not the profile of a company already winning big. I would own it on weakness (200-day near $196, or the $175-180 zone) rather than chase it here, and I would want the Oct 14, 2026 Analyst Day multi-year framework before sizing up.

I applied a justified forward P/E of 16.0x to next-FY (FY27, Aug-2027) consensus EPS of $14.692, giving $235.10 - a ~34% discount to Accenture's 5-year average P/E of 24.17x to reflect the durable step-down to 3-6% local-currency growth, but a clear premium to the 13.5x forward it trades at on 2026-10-04 given 16.8% ROIC, net cash, ~110bp of FY26 margin expansion, and negative accruals (cash ahead of earnings). Cross-checking on cash: FY26 FCF of $11.62B on ~612M shares is ~$19.00/share; a 16x-earnings valuation implies an ~8.1% FCF yield, versus ~9.6% at the current $198.90 - i.e. 16x is the conservative end of the range rather than a stretch, and a 7% fair FCF yield would imply closer to $270.